employee
employee
University of Cambridge (Department of Clinical Veterinary Medicine)
employee
employee
employee
GRNTI 68.41 Ветеринария
Objectives. Previous reports have suggested that hypothyroid and diabetic patients can be predisposed to keratoconjunctivitis sicca. This study aimed to measure tear production in dogs with diabetes, hypothyroidism and hyperadrenocorticism using the Schirmer tear test and to compare these results with Schirmer tear test values for a group of normal dogs. Methods. Schirmer tear tests were performed on 16 dogs with hyperadrenocorticism, 18 with diabetes and 12 with hypothyroidism together with 100 control dogs. Corneal sensitivity was also measured in 12 of the 18 diabetic dogs with a Cochet Bonnet aesthesiometer and compared with age- and breed-matched normal dogs. Results. Schirmer tear test values in dogs with hypothyroidism, hyperadrenocorticism and diabetes were 12.3±3.2, 14.0±4.0 и 12.3±5.3 mm/minutes, respectively. Schirmer tear test values were significantly lower than that for the control group (19.6±4.2 mm/minutes) in all dogs with an endocrinopathy. Only in two hypothyroid dogs and three diabetics, this was manifested as profound keratoconjunctivitis sicca with Schirmer tear test value lower than 5 mm/minutes. Diabetic dogs had significantly reduced corneal sensitivity compared with a matched set of control dogs. Clinical significance. This study shows a significant reduction in tear production in animals with diabetes mellitus, hypothceyroidism and hyperadrenocorticism. Further research is needed to elucidate the mechanisms by which this reduction in tear production occurs. Assessment of tear production should be undertaken in animals diagnosed with these endocrinopathies, as these
keratoconjunctivitis sicca, tear production, Schirmer tear tests, dogs, diabetes mellitus, hypothyroidism, hyperadrenocorticism
1. Barrera R., Mane R.C., Rodriges J.F., Jimenes A., Keratoconjunctivitis sicca and diabetes mellitus in the dog, Journal of the American Animal Hospital Association, 1992, No. 200, pp. 1967-1968.
2. Basher A.W., Roberts S.M., Ocular manifestations of diabetes mellitus: diabetic cataracts in dogs, Veterinary Clinics of North America: Small Animal Practice, 1995, No. 25, pp. 661-676.
3. Van Blokland S.C., Van Helden-Meeuwsen C.G., Wierenga-Wolf A.F., Drexhage H.A., Hooijkaas H., Van de Merwe J.P., Versnel M.A., Two different types of sialoadenitis in the NODand MRL/lpr mouse models for Sjogren’s syndrome: a differential role for dendritic cells in the initiation of sialoadenitis?, Laboratory Investigation, 2000, No. 80, pp. 575-585.
4. Van Blokland S.C., Versnel M.A., Pathogenesis of Sjogren’s syndrome: characteristics of different mouse models for autoimmune exocrinopathy, Clinical Immunology, 2002, No. 103, pp. 111-124.
5. Brennan N.A., Bruce A.S., Aesthesiometry as an indicator of corneal health, Optometry and Visual Science, 1991, No. 68, pp. 699-702.
6. Cha S., Peck A.B., Humphreys-Beher M.G., Progress in understanding autoimmune exocrinopathy using the non-obese diabetic mouse: an update, Critical Reviews in Oral Biology and Medicine, 2002, No. 13, pp. 5-16.
7. Crowe J.P., Christensen E., Butler J., Wheeler P., Doniach D., Keenan J., Williams R., Primary biliary cirrhosis: the prevalence of hypothyroidism and its relationship to thyroid autoantibodies and sicca syndrome, Gastroenterology, 1980, No. 78, pp. 1437-1441.
8. Cullen C.L., Ihle S.L., Webb A.A., McCarville C., Keratoconjunctival effects of diabetes mellitus in the dog, Veterinary Ophthalmology, 2005, No. 8, pp. 215-224.
9. Dogru M., Katakami C., Inoue M., Tear function and ocular surface changes in noninsulindependent diabetes mellitus, Ophthalmology, 2001, No. 108, pp. 586-592.
10. Esch T.R., Poveromov J.D., Aikins M.C., Levanos V.A., A novel lacrimal gland autoantigen in the NOD mouse model of Sjogren’s syndrome, Scandinavian Journal of Immunology, 2002, No. 55, pp. 304-310.
11. Goebbels M., Tear secretion and tear film function in insulin dependent diabetics, British Journal of Ophthalmology, 2000, No. 84, pp. 19-21.
12. Good K.L., Maggs D.J., Hollingsworth S.R., Scagliotti R.H., Nelson R.W., Corneal sensitivity in dogs with diabetes mellitus, American Journal of Veterinary Research, 2003, No. 64, pp. 7-11.
13. Ikegami H., Animal models of autoimmune polyglandular syndrome, Endocrinology and Metabolic Clinics of North America, 2002, No. 31, pp. 431-439.
14. Kaswan R., Pappas C.Jr, Wall K., Hirsh S.G., Survey of canine tear deficiency in veterinary practice, Advances in Experimental Medicine and Biology, 1998, No. 438, pp. 931-939.
15. Khedr E.M., El Toony L.F., Tarkhan M.N., Adbella G., Peripheral and central nervous system alterations in hypothyroidism: electrophysiological findings, Neuropsychobiology, 2000, No. 41, pp. 88-94.
16. Khoo D.H., Eng P.H., Ho S.C., Tai E.S., Morgenthaler N.G., Seah L.L., Fong K.S., Chee S.P., Choo C.T., Aw S.E., Graves’ ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels, Thyroid, 2000, No. 10, pp. 1093-1100.
17. Kiljanski J., Nebes V., Wall J.R., Significance of tissue specific and tissue non specific autoimmune reactions of Graves’ disease, Clinical and Experimental Rheumatology, 1996, No. 15 (Suppl), S 69-S76.
18. Kong L., Robinson C.P., Peck A.B., Vela-Roch N., Sakata K.M., Dang H., Talal N., Humphreysbeher M.G., Inappropriate apoptosis of salivary and lacrimal gland epithelium of immunodeficient NOD-scid mice, Clinical and Experimental Rheumatology, 1998, No. 16, pp. 675-681.
19. Kooistra H.S., Rijnberk A., Van Den Ingh T.S., Polyglandular deficiency syndrome in a boxer dog: thyroid hormone and glucocorticoid deficiency, Veterinary Quarterly, 1995, No. 17, pp. 59-63.
20. Lorenz M., Diagnosis and medical management of canine Cushing’s syndrome: a study of 57 consecutive cases, Journal of the American Animal Hospital Association, 1982, No. 18, pp. 707-716.
21. Manns M.P., Strassburg C.P., Lankisch T., Autoimmune polyglandular syndrome type 1, Experimental and Clinical Endocrinology and Diabetes, 2003, No. 111, pp. 298.
22. Miller P.E., Panciera D.L., Effects of experimentally induced hypothyroidism on the eye and ocular adnexa of dogs, American Journal of Veterinary Research, 1994, No. 55, pp. 692-697.
23. Moore P.A., Bounous D.I., Kaswan R.L., Humphreys-Beher M.G., Histologic examination of the NOD-mouse lacrimal glands, a potential model for idiopathic autoimmune dacryoadenitis in Sjogren’s syndrome, Laboratory Animal Science, 1996, No. 46, pp. 125-128.
24. Nepp J., Abela C., Polzer I., Derbolav A., Wedrich A., Is there a correlation between the severity of diabetic retinopathy and keratoconjunctivitis sicca?, Cornea, 2000, No. 19, pp. 487-491.
25. Obermayer-Straub P., Strassburg C.P., Manns M.P., Autoimmune polyglandular syndrome type 1, Clinical Reviews of Allergy and Immunology, 2000, No. 18, pp. 167-183.
26. Oxholm P., Primary Sjogren’s syndrome - clinical and laboratory markers of disease activity, Seminars in Arthritis and Rheumatism, 1992, No. 22, pp. 114-126.
27. Ozdemir M., Buyukbese M.A., Cetinkaya A., Ozdemir G., Risk factors for ocular surface disorders in patients with diabetes mellitus, Diabetes Research and Clinical Practice, 2003, No. 59, pp. 195-199.
28. Perruccio C., Incidence of hypothyroidism in dogs affected by keratoconjunctivitis sicca. Proceedings of the American College of Veterinary Ophthalmologists, Las Vegas, NV, USA, 1982, pp 47-48.
29. Rocha E.M., De M Lima M.H., Carvalho C.R., Saad M.J., Velloso L.A., Characterization of the insulin-signalling pathway in lacrimal and salivary glands of rats, Current Eye Research, 2000, No. 21, pp. 833-842.
30. Rosenberg M.E., Tervo T.M., Immonen I.J., Muller L.J., Gronhagen-Riska C., Vesaluoma M.H., Corneal structure and sensitivity in type 1 diabetes mellitus. Investigative Ophthalmology and Visual Science, 2000, No. 41, pp. 2915-2921.
31. Ruggeri R.M., Galletti M., Mandolfino M.G., Aragona P., Bartolone S., Giorgianni G., Alesci D., Trimarchi F., Benvenga S., Thyroid hormone autoantibodies in primary Sjogren syndrome and rheumatoid arthritis are more prevalent than in autoimmune thyroid disease, becoming progressively more frequent in these diseases, Journal of Endocrinological Investigation, 2002, No. 25, pp. 447-454.
32. Schatz D.A., Winter W.E., Autoimmune polyglandular syndrome. II: Clinical syndrome and treatment, Endocrinology and Metabolic Clinics of North America, 2002, No. 31, pp. 339-352.
33. Shimomura H., Nakase Y., Furuta H., Nishi M., Nakao T., Hanabusa T., Sasaki H., Okamoto K., Furukawa F., Nanjo K., A rare case of autoimmune polyglandular syndrome type 3, Diabetes Research and Clinical Practice, 2003, No. 61, pp. 103-108.
34. Silva D.G., Socha L., Charlton B., Cowden W., Petrovsky N., Autoimmune diabetes in the NOD mouse: an essential role of Fas-FasL signalling in beta cell apoptosis, Annals of the New York Academy of Science, 2003, No. 1005, pp. 161-165.
35. Tabbara K.F., Vera-Cristo C., Sjogren syndrome. Current Opinion in Ophthalmology, 2000, No. 11, pp. 449-454.
